Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04788043
Title Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stanford University
Indications

Hodgkin's lymphoma

Therapies

Hu5F9-G4 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.